Biote Corp. · NASDAQ:BTMD
Biote — Investor Presentation (March 2025)
26 slides from Biote's investor presentation, Mar 17, 2025
Slide 1: Transforming Healthy Aging
Exhibit 99.1 Transforming Healthy Aging
Slide 2: Forward-Looking Statements
2 Transforming Healthy Aging Forward-Looking Statements Forward-Looking Statements Certain statements in this Presentation may be considered “forward-looking statements” within the meaning of the provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statem
Slide 3: Looking Forward: Our Vision
3 Transforming Healthy Aging Looking Forward Biote offers an Our Vision evidence-based, To be a part of individualized, and everyone’s routine comprehensive healthcare as approach to they age healthcare
Slide 4: Biote by the Numbers
4 Transforming Healthy Aging 1 Biote by the Numbers The Established Leader in Hormone Optimization $197.2M 8,600 2024 Revenue Biote-Certified Practitioners 2 ~5M $58.2M Procedures 2024 Adj. EBITDA Performed 2 29.5% >400,000 2024 Adj. EBITDA Active Patients Margin 1. All information as of December 31
Slide 5: Investment Highlights
5 Transforming Healthy Aging Investment Highlights Proprietary Trusted Leader in Large & Growing Growing, Profitable Technology, Hormone Addressable & Capital-light Clinical, Education Optimization Markets Business Model & Training Platform Becoming the Leading Single-Source Provider of Evidence-Bas
Slide 6: Why Hormone Optimization
6 Transforming Healthy Aging Why Hormone Optimization ~47M Women Hormone Deficiency Impacts Quality of Life and affected with menopausal Heightens Risk of Chronic Disease (8) symptoms Common Hormone deficiency (1) symptoms: increases risk of: (2)(3) • Low energy• Heart disease ~20M Men (4)(5) • Inso
Slide 7: Biote: A Better Solution for Practitioners & Patients
7 Transforming Healthy Aging Biote: A Better Solution for Practitioners & Patients 1 Network of 8,600 certified practitioners • OB/GYN Biote-certified practitioners customize • Family Practice/Internal Medicine treatment therapies based on our • Urology proprietary algorithms to meet each • Function
Slide 8: A More Proactive and Holistic Approach to Healthcare
8 Transforming Healthy Aging A More Proactive and Holistic Approach to Healthcare Practitioners Seek: ▪ Single-source technology platform ▪ Therapies to address common health conditions ▪ Revenue opportunities that enhance clinic economics Patients Seek: ▪ Ease and convenience from a single provider
Slide 9: Becoming a Therapeutic Wellness Leader
9 Biote 2012-2023 Hormone Optimization Leader Biote 2024-2025 Becoming a Therapeutic Wellness Leader Evidence-Based Tech-Enabled + Therapeutics Platform Expansive Portfolio DRIVEN by Comprehensive of Products BEST-IN-CLASS Biote personalized ✓ People ✓ Weight Loss/ BioteRx Body Comp Biote wellness s
Slide 10: Large & Growing Markets
10 Transforming Healthy Aging Large & Growing Markets 82% of US Consumers Consider US Therapeutic Wellness a Top or Important Wellness (10) Priority in their Everyday Lives $400B+ ▪ Growing patient interest in personal health & wellness (10) 5-10% CAGR ▪ Patient desire for evidence-based results Hor
Slide 11: Significant Geographic & Practitioner Expansion Opportunity
11 Transforming Healthy Aging Significant Geographic & Practitioner 1 Expansion Opportunity Practitioner Opportunity 2 Building on our success in our core 260,000 US Practitioners with states to efficiently scale our presence Relevant Specialties ▪ Tech-enabled, franchise- like highly-scalable busin
Slide 12: Nutraceuticals Complement Our Hormone Therapy Offerings
12 Transforming Healthy Aging Nutraceuticals Complement Our Hormone Therapy Offerings ▪ Biote-branded dietary supplements and cosmeceuticals ▪ Complementary to procedures performed by Biote-certified practitioners ▪ Nutraceuticals strengthen the patient connection to Biote and enhance practitioner e
Slide 13: BioteRx: New Therapeutic Wellness Offerings
13 Transforming Healthy Aging BioteRx: New Therapeutic Wellness Offerings from a Trusted Network of Providers Wellness Categories Hormone Optimization Weight Loss/ Thyroid Body Composition Health Sexual Preventive Health Wellness Hair Loss/ Aesthetic Dermatology
Slide 14: Our Scalable & Proprietary Platform Drives Clinic Success
14 Transforming Healthy Aging Our Scalable & Proprietary Platform Drives Clinic Success + + + + = The Biote Method Clinical Didactic & Access to Practice Practice Proprietary Decision High Quality Training Clinical Retention Practice Support Certification Products and Support Management Software Tra
Slide 15: Commitment to Research
15 Commitment to Research Transforming Healthy Aging ▪ The Aging Male Leadership in Education, ▪ European Journal of Breast Health ▪ Therapeutic Advances in Endocrinology and Metabolism Training & Research (14) Breast Cancer Study ▪ Testosterone and/or Testosterone/Estradiol delivered subcutaneously
Slide 16: 2024 Financial Results & 2025 Outlook
16 Transforming Healthy Aging 2024 Financial Results & 2025 Outlook 2025 Guidance ▪ Revenue: 2024 Results $202M - $208M ▪ $197.2M Revenue . 1 (+6.4% y/y) ▪ Adj EBITDA 1 $59M-$64M ▪ $58.2M Adj. EBITDA (+5.4% y/y) Q1 2025 Outlook 1 ▪ 29.5% Adj. EBITDA Margin ▪ Revenue is expected to be ▪ 6.6% Procedur
Slide 17: Capital Allocation Priorities
17 Transforming Healthy Aging Capital Allocation Priorities Organic Drive growth, gain efficiency and expand capabilities Investments Company agreed to repurchase ~18.4 million shares from founder on fixed terms (binding settlement term sheet) and cancelled 3.9 million earnout shares Share Company a
Slide 18: Strengthened Capabilities
18 Transforming Healthy Aging Strengthened Capabilities ▪ Strategic acquisition strengthens control over our supply chain and enhances our efficiency ▪ Deep expertise in 503B manufacturing ▪ Enables longer-term development of innovative wellness therapeutics ▪ Vertical integration of manufacturing p
Slide 19: Our 2025 Priorities
19 Transforming Healthy Aging Our 2025 Priorities ▪ Strengthen our efforts to maximize the value from our top-tier providers ▪ Fully leverage the capabilities of our enhanced clinical decision support software ▪ Continue to develop more high-value and differentiated offerings for our practitioners a
Slide 20: Key Takeaways
20 Transforming Healthy Aging Key Takeaways ▪ Leveraging our leadership in hormone optimization to capture the significant growth opportunity in therapeutic wellness ▪ Our addressable market is substantial, and that we have only just begun to tap into the geographic expansion opportunity in front of
Slide 21: Thank You
21 Thank You
Slide 22: Appendix A
22 Appendix A
Slide 23: Reconciliation of Adjusted EBITDA to Net (Loss) Income
23 Reconciliation of Adjusted EBITDA to Net (Loss) Income
Slide 24: Reconciliation of Adjusted EBITDA to Net (Loss) Income
24 Reconciliation of Adjusted EBITDA to Net (Loss) Income
Slide 25: Appendix B
25 Appendix B
Slide 26: Sources
26 Sources (1) Cardozo et al. Am J OB/GYN, 1984. (2)Mechanisms of testosterone deficiency-related endothelial dysfunction. Antonopoulous AS and Antoniades C. Hellenic J Cardiol. 2018 Jun 8. pii:@1109-9666(18)30168-4. (3)Abraham Morgantaler et al., Testosterone therapy and cardiovascular Risk: Advanc